AN EVALUATION OF NASAL RESPONSE FOLLOWING DIFFERENT TREATMENT REGIMESOF OXYMETAZOLINE WITH REFERENCE TO REBOUND CONGESTION

Citation
S. Morris et al., AN EVALUATION OF NASAL RESPONSE FOLLOWING DIFFERENT TREATMENT REGIMESOF OXYMETAZOLINE WITH REFERENCE TO REBOUND CONGESTION, American journal of rhinology, 11(2), 1997, pp. 109-115
Citations number
20
Categorie Soggetti
Otorhinolaryngology
ISSN journal
10506586
Volume
11
Issue
2
Year of publication
1997
Pages
109 - 115
Database
ISI
SICI code
1050-6586(1997)11:2<109:AEONRF>2.0.ZU;2-B
Abstract
This was a randomized double-blind vehicle controlled study aimed at i nvestigating the effects on nasal function of 7 days treatment with th e topical decongestant oxymetazoline (0.05% w/v). Fifty healthy volunt eers took part in the study and these were randomly allocated to three treatment groups (i) daily oxymetazoline (b.i.d. 150 mu l per nostril ) (ii) intermittent oxymetazoline, with oxymetazoline being substitute d for vehicle at the morning doses on days 1, 3, and 7; and (iii) dail y vehicle (b.i.d. 150 mu l per nostril). The nasal airway was assessed by measurement of nasal airway resistance (NAR) using posterior rhino manometry, subjective scaling of nasal patency by means of a visual an alogue scale (VAS), and clinical visual examination. On days 1, 2, 3, and 7, NAR and VAS measurements were obtained before the morning dose and up to 6 hours after dosing; clinical visual examinations were also performed before dosing on these days. NAR and VAS measurements were also made following withdrawal of treatment on Days 8 and 9. Nonparame tric analysis of the results showed that therapeutic tolerance to oxym etazoline did not develop over the 7-day treatment period, and visual examination of the nasal mucosa failed to find significant evidence of rhinitis. Evidence of rebound nasal congestion was found following 3 days of oxymetazoline treatment, with baseline NAR within the daily an d intermittent oxymetazoline groups being significantly greater on Day 3 compared to Day 1 (p < 0.05). However, there was a trend toward inc reasing baseline NAR in the vehicle group over the course of the study , suggesting that the vehicle may have contributed to the rebound cong estion. Following the withdrawal of treatments, only the intermittent oxymetazoline group had significantly higher NAR on Days 8 and 9 compa red to Day 1 (p < 0.05). Subjective VAS measurements generally followe d trends in NAR.